WHAT'S INSIDE
 New innovative solution | DNA Encoded Libraries & WuXi HitS Target-to-Hit Platform
Upcoming events | WuXi Webinar on CRISPR Library Screen to Identify Driver Mutations of Tumor Growth and Metastasis
Innovation that Matters | Apitope’s Research
Let Science Lead | WuXi Resources | A Special Online Forum on COVID-19

WuXi AppTec has recently launched the HitS (Hit Success) Business Unit to integrate upstream and downstream technologies of DEL to better empower the early stage drug discovery process.

In this Webinar, Dr. Yong Cang will present case studies applying customized CRISPR/Cas9 libraries to screen for genes that control cancer cell sensitivity in order to target therapeutic agents and
T cell-mediated elimination in vitro and in vivo.

The following topics will be discussed in this webinar:

  • Synthetic lethal screens for mutations with chemical inhibitors or immune checkpoint blockers
  • Application of in vivo CRISPR screen for metastatic drivers in cancer cells against host immunity
  • Novel approaches for oncology and onco-immunology target discovery 
"Although still in its infancy, pharmacogenomics and its role in personalized medicine is likely to be a game-changer and become routine standard of medical care over the coming years," says Apitope's CEO, Hayley French, Ph.D.

This 18-speaker forum created a strong platform for professionals within industry and academia to discuss the challenges seen in the global management of the COVID-19.
Topics such as: diagnosis, therapeutic intervention, vaccine development and global preparedness were keenly discussed in conjunction with patient-focused solutions.